Xavier Deschênes-Simard, MD-CM, PhD, FRCPC

Cyclophosphamide mitigates non-ICANS neurotoxicities following ciltacabtagene autoleucel treatment url:https://ashpublications.org/blood/article-abstract/145/23/2788/536434/Cyclophosphamide-mitigates-non-ICANS

Higher ORR and CR rate in less heavily pretreated patients suggest that this regimen, as an earlier treatment, may improve outcomes. buff.ly/bi4dpzR #hemesky #clinicaltrialsandobservations

I usually refrain from sharing political views on these platforms, as I prefer to focus on scientific advancements. However, today I see it as an educational opportunity. I’m not sure everyone south of the border fully realizes the impact this is having and will continue to have for years to come.

🌴#Tandem25, Thursday @ 6:45pm🍍
Hyperferritinemia syndromes following CD19 CAR T cells for Lymphoma
- Hyperferritinemia (HF) = inferior survival.
- HF = greater toxicity.
- HLH-like manifestations in 28% of patients.
- Impact of HF independent of CRS, ICANS, and tumor burden.
#lymsm, #CARTCell

Nice work by one of our @mskcancercenter.bsky.social BMT fellows Moataz Ellithi on Neurotoxicity and Rare Adverse Events in BCMA-Directed #CARTCells: Real-World FAERS Data - Now out in @astct.bsky.social journal #mmsm www.astctjournal.org/article/S266...

Excellent presentation by Dr. Sehn on Tafa-R2 in relapsed/refractory follicular lymphoma at #ASH2024. InMIND: ''adding tafasitamab to R2 resulted in a 57% reduction in the risk of progression, relapse, or death''.

Liso-Cel Shows Broad Spectrum Activity in CIBMTR Cohort of Relapsed/Refractory LBCL Liso-cel demonstrated safety and efficacy outcomes that were comparable to those in the pivotal TRANSFORM and PILOT trials in patients with relapsed/refractory large B-cell lymphoma.

Liso-cel demonstrated safety and efficacy outcomes that were comparable to those in the pivotal TRANSFORM and PILOT trials in patients with relapsed/refractory large B-cell lymphoma. #lymsm #ash24 #CARTcells

www.onclive.com/view/liso-ce...

Overall response rate (ORR) of 100%! Now with long term data showing 5-yr-Progression Free Survival (PFS) of 91%.

Neither Pembro nor GVD alone is as efficacious, begging the mechanistic question of “synergy” - that is, how do immunotherapy and chemotherapy combine to become more than either alone?

🩸#ASH24 Sunday @ 6pm🩸
Real-world comparison of CD19 CAR T cells for LBCL.
- 501 patients from 4 centers.
- Inferior outcomes with tisa-cel.
- Higher ORR and CR rates with liso-cel.
- Liso-cel and axi-cel = similar PFS and OS rates.
- Less toxicities with liso-cell.
#lymsm, #CARTCell

Come and check out @mskcancercenter.bsky.social Kai Rejeski's talk on #CARTcells toxicity #ASH24
👉 In CAR-TOGRAPHY we graded >32,500 pt days across 4 sites in 902 CAR-T recipients, yielding >125,000 unique toxicity datapoints.
👉 Develop new metrics to describe early toxicity: CTI & tox phenotypes

🩸#ASH24 Sunday @ 12:15pm🩸
Point-of-care vs commercial CD19 CAR-T therapies.
- Median vein-to-vein time: POC=11d, axi-cel=38d, tisa-cel=44d.
- Grade 2+ CRS: POC=26%, axi-cel=52%, tisa-cel=37%.
- Comparable survival outcomes.
#lymsm, #CARTCell

! Hot off the press !
Excited to share this interesting case of long-term axi-cel persistence and to brainstorm about the role of immune checkpoint inhibitors in CAR T-cell therapies.
doi.org/10.1080/1042...

#lymphoidneoplasia, #CART, #Immunotherapy

I am happy to share our new article in
@BloodJournal
. Acute myelopathy is a rare but devastating complication of CAR T-cell therapy: authors.elsevier.com/a/1k5wW1UYwn...

#CART #CellTherapy #Lymphoma #All